New antibiotics and antimicrobial combination therapy for the treatment of gram-negative bacterial infections

journals.lww.com September 3, 2018

Only few new molecules have an adequate activity against MDR gram-negative pathogens, especially carbapenemase-producer strains. Among these, ceftozolane/tazobactam has been recently approved for clinical use. Other compounds, such as avibactam combinations, plazomicin, and eravacycline, have shown promising activity in phase 2 and 3 clinical trials. A limited number of large trials have assessed the treatment options for commonly encountered resistant pathogens